Thursday, July 26, 2007

The eye cancer field has really heated up in the past few years, which has added to everyone's stress over publications and grants, but has also elevated a once second-tier cancer to the limelights. Of course, the old guard are still working desparately to stay relevant, but many are resistant to the changing face of scientific research. Here's an example of an article that is clearly trying to move ahead, but has missed that most important leap:

Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Peer J. (2007) "Serum markers to detect metastatic uveal melanoma." Anticancer Research 27(4A):1897-900.

Here's the European competition along the same lines, but modernified:

Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, Thiel E, Foerster MH, Keilholz U. (2007) "Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma." Clinical Cancer Research 13(4):1171-8.

Can you spot the major differences?

No comments: